Yvan Beaussant1, James Tulsky1,2, Benjamin Guérin3,4, Claudia Schwarz-Plaschg5, Justin J Sanders1,2. 1. Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 2. Division of Palliative Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. 3. Laboratoire Logiques de l'Agir EA 2274, Université de Franche-Comté, Besançon, France. 4. Laboratoire de Neurosciences Intégratives et Cliniques, Université de Franche-Comté, Besançon, France. 5. Department of Science and Technology Studies, University of Vienna, Vienna, Austria.
Abstract
Background: With support from the Radcliffe Institute for Advanced Study at Harvard University, we convened researchers representing palliative care, psychosocial oncology, spiritual care, oncology, and psychedelic-assisted therapies. We aimed to define priorities and envision an agenda for future research on psychedelic-assisted therapies in patients with serious illness. Over two days in January 2020, participants engaged in an iterative series of reflective exercises that elicited their attitude and perspectives on scientific opportunities for this research. Objectives: The aim of the study is to identify themes that shape priorities and an agenda for research on psychedelic-assisted therapy for those affected by serious illness. Methods: We collected data through preconference interviews, audio recordings, flip charts, and sticky notes. We applied thematic qualitative analysis to elucidate key themes. Results: We identified seven key opportunities to advance the field of psychedelic-assisted therapies in serious illness care. Four opportunities were related to the science and design of psychedelic-assisted therapies: clarifying indications; developing and refining therapeutic protocols; investigating the impact of set and setting on therapeutic outcomes; and understanding the mechanisms of action. The other three pertained to institutional and societal drivers to support optimal and responsible research: education and certification for therapists; regulations and funding; and diversity and inclusion. Additionally, participants suggested epistemological limitations of the medical model to understand the potential value and therapeutic use of psychedelics. Conclusions: Medicine and society are witnessing a resurgence of interest in the effects and applications of psychedelic-assisted therapies in a wide range of settings. This article suggests key opportunities for research in psychedelic-assisted therapies for those affected by serious illness.
Background: With support from the Radcliffe Institute for Advanced Study at Harvard University, we convened researchers representing palliative care, psychosocial oncology, spiritual care, oncology, and psychedelic-assisted therapies. We aimed to define priorities and envision an agenda for future research on psychedelic-assisted therapies in patients with serious illness. Over two days in January 2020, participants engaged in an iterative series of reflective exercises that elicited their attitude and perspectives on scientific opportunities for this research. Objectives: The aim of the study is to identify themes that shape priorities and an agenda for research on psychedelic-assisted therapy for those affected by serious illness. Methods: We collected data through preconference interviews, audio recordings, flip charts, and sticky notes. We applied thematic qualitative analysis to elucidate key themes. Results: We identified seven key opportunities to advance the field of psychedelic-assisted therapies in serious illness care. Four opportunities were related to the science and design of psychedelic-assisted therapies: clarifying indications; developing and refining therapeutic protocols; investigating the impact of set and setting on therapeutic outcomes; and understanding the mechanisms of action. The other three pertained to institutional and societal drivers to support optimal and responsible research: education and certification for therapists; regulations and funding; and diversity and inclusion. Additionally, participants suggested epistemological limitations of the medical model to understand the potential value and therapeutic use of psychedelics. Conclusions: Medicine and society are witnessing a resurgence of interest in the effects and applications of psychedelic-assisted therapies in a wide range of settings. This article suggests key opportunities for research in psychedelic-assisted therapies for those affected by serious illness.
Authors: Karen E Steinhauser; George Fitchett; George F Handzo; Kimberly S Johnson; Harold G Koenig; Kenneth I Pargament; Christina M Puchalski; Shane Sinclair; Elizabeth J Taylor; Tracy A Balboni Journal: J Pain Symptom Manage Date: 2017-07-18 Impact factor: 3.612
Authors: David Hui; Maxine de la Cruz; Steve Thorney; Henrique A Parsons; Marvin Delgado-Guay; Eduardo Bruera Journal: Am J Hosp Palliat Care Date: 2010-11-07 Impact factor: 2.500
Authors: Brian T Anderson; Alicia Danforth; Prof Robert Daroff; Christopher Stauffer; Eve Ekman; Gabrielle Agin-Liebes; Alexander Trope; Matthew Tyler Boden; Prof James Dilley; Jennifer Mitchell; Joshua Woolley Journal: EClinicalMedicine Date: 2020-09-24
Authors: Tracy Anne Balboni; Mary Elizabeth Paulk; Michael J Balboni; Andrea C Phelps; Elizabeth Trice Loggers; Alexi A Wright; Susan D Block; Eldrin F Lewis; John R Peteet; Holly Gwen Prigerson Journal: J Clin Oncol Date: 2009-12-14 Impact factor: 44.544
Authors: Keith G Wilson; Tracy L Dalgleish; Harvey Max Chochinov; Srini Chary; Pierre R Gagnon; Karen Macmillan; Marina De Luca; Fiona O'Shea; David Kuhl; Robin L Fainsinger Journal: BMJ Support Palliat Care Date: 2014-03-04 Impact factor: 3.568
Authors: Roland R Griffiths; Matthew W Johnson; Michael A Carducci; Annie Umbricht; William A Richards; Brian D Richards; Mary P Cosimano; Margaret A Klinedinst Journal: J Psychopharmacol Date: 2016-12 Impact factor: 4.153
Authors: Li Juanjuan; Cesar Augusto Santa-Maria; Feng Hongfang; Wang Lingcheng; Zhang Pengcheng; Xu Yuanbing; Tan Yuyan; Liu Zhongchun; Du Bo; Lan Meng; Yang Qingfeng; Yao Feng; Tu Yi; Sun Shengrong; Li Xingrui; Chen Chuang Journal: Clin Breast Cancer Date: 2020-06-07 Impact factor: 3.225
Authors: William E Rosa; Zachary Sager; Megan Miller; Ilan Bernstein; Alden Doerner Rinaldi; Katie Addicott; Michael Ljuslin; Chris Adrian; Anthony L Back; Jamie Beachy; Anthony P Bossis; William S Breitbart; Mary P Cosimano; Stacy M Fischer; Jeffrey Guss; Emma Knighton; Janis Phelps; Brian D Richards; William A Richards; James A Tulsky; Monnica T Williams; Yvan Beaussant Journal: J Palliat Med Date: 2022-03-14 Impact factor: 2.947